You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
Login
Username:

Password:


Related Headlines

Alfasigma SpA collaborates with Innovative Molecules GmbH on potential treatment for HSV encephalitis

Transneural Therapeutics presents new data on TN-001 at 64th Annual Meeting of ACNP

US FDA accepts IND application for AskBio's AB-1009

Cereno Scientific publishes first peer-reviewed data on CS014, highlighting antithrombotic efficacy without bleeding risk

Rakuten Medical signs manufacturing agreement with LOTTE Biologics

ElpasBio partners with Fosun Kairos on AlloJoin stem cell therapy

argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis

TetraScience collaborates with Thermo Fisher Scientific to accelerate scientific data and AI enablement

Curasight reports preliminary data from Phase 1 trial in patients with high-grade gliomas

Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA

WuXi Biologics granted UK GMP certification for two manufacturing facilities in Wuxi

Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735

NewcelX reports positive biomaterial study results supporting stem cell islet delivery without immune suppression

Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer

Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026